Hypertension, Pregnancy-Induced Clinical Trial
Official title:
A Comparison of Spot Test (Urine Protein/Creatinine Ratio) With 24 - Hour Urine Protein Excretion in Woman With Hypertensive Disorders of Pregnancy
Verified date | January 2018 |
Source | Saint Thomas Hospital, Panama |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The presence of proteinuria (>300 mg/d) represents an important factor in the diagnosis and
evaluation of the pregnant patient with an hypertensive disorder. The 24 hour collection of
urine for proteinuria is the gold standard for the diagnosis of the condition and allows the
physician to determine if an hypertensive disorder is related directly or not to the
gestation.
The problem is the time it takes and the technical difficulties related to the sample
collection. An alternative is the quantification of protein and creatinine in a random sample
of urine. We seek to evaluate if this method is as affective as the gold standard in the
diagnosis of proteinuria (>300 mg/d).
Status | Completed |
Enrollment | 420 |
Est. completion date | July 2016 |
Est. primary completion date | June 2016 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: - Pregnant women with 28 weeks or more of gestation. - Complete collection of the 24 hour urine sample. Exclusion Criteria: - Failure to recollect the 24 hour urine sample. - Pregestational Diabetes - Kidney disease - 24 hour urine protein > 8.0 g/dL or seric creatinine > 2.0 mg/dL (it could indicate kidney disease). |
Country | Name | City | State |
---|---|---|---|
Panama | Saint Thomas H | Panama |
Lead Sponsor | Collaborator |
---|---|
Saint Thomas Hospital, Panama |
Panama,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Sensitivity and Specificity | The number of patients with a 24 hour urine collection with a proteinuria > 300mg will be compared with the number of patients with a Spot Test (protein/creatinine ratio in a random urine sample) > 0.2 (equivalent to the 24 hour test > 300 mg). This value will be used to calculate the Sensitivity and Specificity of the spot test. | Six months | |
Secondary | Positive and Negative Predictive Value | The number of patients with a 24 hour urine collection with a proteinuria > 300mg will be compared with the number of patients with a Spot Test (protein/creatinine ratio in a random urine sample) > 0.2 (equivalent to the 24 hour test > 300 mg). This value will be used to calculate the positive and negative predective value of the spot test. | six months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03613714 -
Innovation in Postpartum Care for Women With Hypertensive Disorders of Pregnancy
|
N/A | |
Completed |
NCT02338687 -
Low Dose Calcium to Prevent Preeclampsia
|
Phase 4 | |
Completed |
NCT04752475 -
Lasix for the Prevention of De Novo Postpartum Hypertension
|
Phase 3 | |
Completed |
NCT03334149 -
Blood Pressure Monitoring in High Risk Pregnancy to Improve the Detection and Monitoring of Hypertension
|
N/A | |
Recruiting |
NCT03298802 -
Postpartum Management of Hypertension in Pregnancy With Hydrochlorothiazide
|
Phase 3 | |
Completed |
NCT03076619 -
A Clinical Study of Fundus Findings in Toxaemia of Pregnancy
|
N/A | |
Recruiting |
NCT05473767 -
Expanding the Family Check-Up in Early Childhood to Promote Cardiovascular Health of Mothers and Young Children
|
N/A | |
Completed |
NCT03356106 -
Screening and Treatment of Obstructive Sleep Apnea in High-risk Pregnancy
|
N/A | |
Recruiting |
NCT05849103 -
Comprehensive Postpartum Management for Women With Hypertensive Disorders of Pregnancy
|
N/A | |
Recruiting |
NCT03200743 -
Catestatin and Hypertension in Pregnancy
|
N/A | |
Terminated |
NCT04343235 -
Postpartum Management of Gestational Hypertensive Disorders Using Furosemide
|
Phase 4 | |
Active, not recruiting |
NCT04580927 -
Breastfeeding and Postpartum Cardiovascular Health
|
N/A | |
Recruiting |
NCT03858595 -
Optimizing Gestational Weight Gain, Birth Weight and Other Perinatal Outcomes Among Pregnant Women at Risk of Hypertension in Pregnancy
|
N/A | |
Recruiting |
NCT05655936 -
Eliminating Severe Maternal Morbidity With Heart Health Doulas Trial
|
N/A | |
Completed |
NCT01736826 -
Free DNA and Nucleosome Concentrations in Pathological Pregnancies
|
||
Completed |
NCT02523781 -
Evaluation of an Information Pamphlet for Postpartum Women That Had a Hypertensive Pregnancy
|
N/A | |
Completed |
NCT03556761 -
Furosemide for Accelerated Recovery of Blood Pressure Postpartum
|
Phase 2 | |
Completed |
NCT00949260 -
Hemodynamic Assessment of Healthy and Hypertensive Pregnant Women by Non-Invasive Bio-Reactance
|
N/A | |
Active, not recruiting |
NCT04012151 -
Arm and Finger Measurement for Blood Pressure Surveillance
|
||
Completed |
NCT04615624 -
Furosemide vs. Placebo for Severe Antepartum Hypertension
|
Phase 3 |